patient identification
Recently Published Documents


TOTAL DOCUMENTS

582
(FIVE YEARS 218)

H-INDEX

22
(FIVE YEARS 4)

2021 ◽  
Vol 17 (2) ◽  
pp. 80-88
Author(s):  
Hendri Poernomo ◽  
◽  
Maya Sari Dewi ◽  

Introduction: Generally, paresthesia are a pain or uncomfortable sense or abnormality feeling like a burned, sweating, etc. The symptoms can be temporary or permanent, an acute nerve injury will reduce risk of permanent paresthesia. Review: Paresthesia can caused by local anesthesia ( injection method), extraction of third molar, dental implant, endodontic treatment, and trauma. It can prevented by proper patient identification, treatment planning and procedure. The management of paresthesia are observation, Physiologic treatment (cryotherapy, electro-iontophoresis, heat-therapy, massage treatment or acupunture), pharmacology therapy (antibiotics, anti-inflamation, antidepressant, neurotropic group, and topical), phsychologic therapy and laser therapy. Conclusion: Using Laser for paresthesia are to accelerate and enhanced regeneration the nerve tissue. With low-level laser it wiil be e xpected to healing an injured nerve.


2021 ◽  
Vol 5 ◽  
pp. 179
Author(s):  
Alinani Simukanga ◽  
Misaki Kobayashi ◽  
Lauren Etter ◽  
Wenda Qin ◽  
Rachel Pieciak ◽  
...  

Background Accurate patient identification is essential for delivering longitudinal care. Our team developed an ear biometric system (SEARCH) to improve patient identification. To address how ear growth affects matching rates longitudinally, we constructed an infant cohort, obtaining ear image sets monthly to map a 9-month span of observations. This analysis had three main objectives: 1) map trajectory of ear growth during the first 9 months of life; 2) determine the impact of ear growth on matching accuracy; and 3) explore computer vision techniques to counter a loss of accuracy.   Methodology Infants were enrolled from an urban clinic in Lusaka, Zambia. Roughly half were enrolled at their first vaccination visit and ~half at their last vaccination. Follow-up visits for each patient occurred monthly for 6 months. At each visit, we collected four images of the infant’s ears, and the child’s weight. We analyze ear area versus age and change in ear area versus age. We conduct pair-wise comparisons for all age intervals. Results From 227 enrolled infants we acquired age-specific datasets for 6 days through 9 months. Maximal ear growth occurred between 6 days and 14 weeks. Growth was significant until 6 months of age, after which further growth appeared minimal. Examining look-back performance to the 6-month visit, baseline pair-wise comparisons yielded identification rates that ranged 46.9–75%. Concatenating left and right ears per participant improved identification rates to 61.5–100%. Concatenating images captured on adjacent visits further improved identification rates to 90.3–100%. Lastly, combining these two approaches improved identification to 100%. All matching strategies showed the weakest matching rates during periods of maximal growth (i.e., <6 months). Conclusion By quantifying the effect that ear growth has on performance of the SEARCH platform, we show that ear identification is a feasible solution for patient identification in an infant population 6 months and above.


Computation ◽  
2021 ◽  
Vol 9 (12) ◽  
pp. 133
Author(s):  
Maria Camila Guerrero ◽  
Juan Sebastián Parada ◽  
Helbert Eduardo Espitia

According to the behavior of its neuronal connections, it is possible to determine if the brain suffers from abnormalities such as epilepsy. This disease produces seizures and alters the patient’s behavior and lifestyle. Neurologists employ the electroencephalogram (EEG) to diagnose the disease through brain signals. Neurologists visually analyze these signals, recognizing patterns, to identify some indication of brain disorder that allows for the epilepsy diagnosis. This article proposes a study, based on the Fourier analysis, through fast Fourier transformation and principal component analysis, to quantitatively identify patterns to diagnose and differentiate between healthy patients and those with the disease. Subsequently, principal component analysis can be used to classify patients, employing frequency bands as the signal features. Besides, it is made a classification comparison before and after using principal component analysis. The classification is performed via logistic regression, with a reduction from 5 to 4 dimensions, as well as from 8 to 7, achieving an improvement when there are 7 dimensions in the precision, recall, and F1 score metrics. The best results obtained, without PCA are: precision 0.560, recall 0.690, and F1 score 0.620; meanwhile, the best values obtained using PCA are: precision 0.734, recall 0.787, and F1 score 0.776.


2021 ◽  
Vol 5 (Supplement_1) ◽  
pp. 167-167
Author(s):  
Anna Rahman ◽  
Sindy Lomeli ◽  
Susan Enguidanos

Abstract In 2017, we received funding form the Patient-Centered Outcomes Research Institute to conduct a large, state-wide, randomized controlled trial to test the effectiveness of a home-based palliative care (HBPC) program within accountable care organizations. Participants were randomized to either HBPC or enhanced usual care, where physicians were provided added training and support in core palliative care practices. Originally, we planned to obtain patient referrals to the trial from primary care physicians, however we were unable to engage primary care physicians in patient identification processes. In this session we will describe the numerous trial modifications made to our trial recruitment methods and the success of each approach. Ultimately, after 20 months of trial recruitment, we had recruited just 28 patients and 10 of their caregivers. Findings from this terminated trial may inform other researchers in development of participant recruitment methods.


Author(s):  
Priya S. Kishnani ◽  
Walla Al-Hertani ◽  
Manisha Balwani ◽  
Özlem Göker-Alpan ◽  
Heather A. Lau ◽  
...  

2021 ◽  
Vol 6 (2) ◽  
pp. 96-109
Author(s):  
Bokhee Park ◽  
◽  
Joo Hyun Kim ◽  
Mi Kyung Choi ◽  
Sunhee Nam ◽  
...  

2021 ◽  
Author(s):  
Tuba Ulgen ◽  
Özlem Uğur

Abstract Purpose: Caregivers have to manage tasks at home such as providing management of the patient’s follow-up. Social support is known to have protective effects, especially for family members and caregivers for cancer patients. The aim of this study is to investigate the effect of care on home care and perceived social support on cancer burden. Methods: A descriptive and cross-sectional study. This study was conducted in the Chemotherapy Day Treatment Unit of a University Research and Application Hospital. a 222 patients were included in the study. In this study, Caregiver and Patient Identification Form, Caregiver's Home Care Practices Questionnaire Form, Zarit Caregiver Burden Scale, Perceived Multidimensional Social Support Scale, Karnofsky Performance Scales were used. The data of the study were collected by face-to-face interviews conducted with the caregivers. Results: In our research the social support level was found to be moderately adequate and had a mild maintenance burden. In our study, when the relationship between the multidimensional perceived social support scale scores and the Zarit care load scale scores is examined it was found that there was a significant relation between the perceived social support total scores of caregivers and the care burden scores in a weak and negative way (p <.01). Conclusion: It has been determined that the caregivers of cancer patients have taken care of their home care practices and the perceived lack of social support.


Blood ◽  
2021 ◽  
Vol 138 (Supplement 1) ◽  
pp. 4991-4991
Author(s):  
Carl E. Allen ◽  
Jennifer Leiding ◽  
Shanmuganathan Chandrakasan ◽  
Kelly J. Walkovich ◽  
Abiola Oladapo ◽  
...  

Abstract Introduction: Hemophagocytic lymphohistiocytosis (HLH) is a rare, life-threatening hyperinflammatory syndrome characterized by overactivation of the immune system due to systemic release of proinflammatory cytokines, especially of interferon gamma (IFNγ), and persistent activation of macrophages/histiocytes and T cells. Emapalumab, a fully human, anti-IFNγ monoclonal antibody that binds to both free and receptor-bound IFNy, neutralizing its biologic activity, was approved by the Food and Drug Administration (FDA) in 2018 for the treatment of adult and pediatric patients with primary HLH with refractory, recurrent or progressive disease or intolerance with conventional HLH therapy. The safety and efficacy of emapalumab was based on results from a pivotal phase 2/3 trial which reported a 63% overall response in patients treated with emapalumab. Since approval, no study has evaluated the use of emapalumab in a larger cohort of patients in the real-world clinical setting. Aim: To assess real-world treatment patterns and outcomes, clinical and demographic characteristics among patients treated with emapalumab. Method: This retrospective, non-interventional, observational medical chart review study will include patients treated across treatment centers in the US with emapalumab in a non-clinical trial setting. The study aims to include more than 100 patients who have been treated with at least one dose of emapalumab between November 20, 2018 and December 31, 2020 (patient identification period). The date that the patient initiates treatment with emapalumab within the patient identification period is defined as the index date. The post-index date is defined as the period from the index date through to the study end date (June 30, 2021), end of data availability for the patient, or date of death, whichever occurs first. Patients will be classified into three groups (i.e. primary HLH, secondary HLH, or non-HLH) based on the information obtained from their charts, the HLH 2004 diagnostic criteria, and adjudication by the REAL-HLH Steering Committee. Results: The primary objective of the study is to describe treatment patterns in patients with HLH treated with emapalumab in a real-world clinical setting, including emapalumab dose, treatment duration, and reasons for initiating or discontinuing treatment. The secondary objectives are to describe demographic and clinical characteristics of patients with HLH treated with emapalumab, and their outcomes. The exploratory objectives include detailing the demographic, clinical characteristics, treatment patterns, and outcomes of patients with non-HLH clinical conditions treated with emapalumab (Table 1). Demographics and clinical characteristics will be analyzed at the time of diagnosis. Treatment patterns and outcomes will be analyzed during the post-index date. Conclusion: The study aims to assess treatment patterns and outcomes, clinical and demographic characteristics among patients treated with emapalumab, a novel IFNγ blocking agent, in real-world clinical settings in the US. Figure 1 Figure 1. Disclosures Allen: Sobi: Consultancy. Leiding: Sobi: Consultancy. Chandrakasan: Sobi: Consultancy. Walkovich: X4 Pharmaceuticals: Other: Local PI for clinical trial involving mavorixafor and patients with neutropenia; Swedish Orphan Biovitrum AB (Sobi): Consultancy, Honoraria; Pharming: Honoraria, Membership on an entity's Board of Directors or advisory committees; Horizon Pharmaceuticals: Honoraria, Membership on an entity's Board of Directors or advisory committees. Oladapo: Sobi: Current Employment. Yee: Sobi: Current Employment. Pednekar: Sobi: Consultancy; PRECISIONheor: Current Employment. Raza: Sobi: Consultancy; PRECISIONheor: Current Employment. Jordan: Sobi: Consultancy.


Sign in / Sign up

Export Citation Format

Share Document